INTRODUCTION
• Respiratory beta2-agonists are primarily used to treat reversible airway disease. They are Food and Drug Administration (FDA)-approved for the treatment of asthma, chronic obstructive pulmonary disease (COPD), exercise-induced asthma/bronchospasm, and/or reversible bronchospasm.
• Asthma is a chronic lung disease that inflames and narrows the airways, making it difficult to breathe. Asthma causes recurring periods of wheezing, chest tightness, shortness of breath, and coughing. Asthma affects people of all ages, but most often starts during childhood. In the United States, more than 25 million people are known to have asthma, including about 7 million children. The exact cause(s) of asthma are unknown. A combination of factors such as genetics, certain respiratory infections during childhood, and contact with airborne allergens can contribute to its development. Most patients with asthma have allergies (National Heart, Lung, and Blood Institute [NHLBI] 2014).
  ○ Current pharmacologic options for asthma management are categorized as: (1) long-term control medications to achieve and maintain control of persistent asthma, and (2) quick-relief medications used to treat acute symptoms and exacerbations.
  ○ Long-term control medications for asthma include (NHLBI 2007):
    ▪ Corticosteroids (inhaled corticosteroids [ICSs] for long-term control; short courses of oral corticosteroids to gain prompt control of disease, long-term oral corticosteroids for severe persistent asthma)
    ▪ Cromolyn sodium and nedocromil
    ▪ Immunomodulators (ie, omalizumab)
    ▪ Leukotriene modulators
    ▪ Long-acting beta2-agonists (LABAs)
    ▪ Methylxanthines (ie, theophylline)
  ○ Quick-relief medications for asthma include (NHLBI 2007):
    ▪ Anticholinergics (ie, ipratropium bromide), as an alternative bronchodilator for those not tolerating a short-acting beta2-agonist (SABA)
    ▪ SABAs (therapy of choice for relief of acute symptoms and prevention of exercise-induced bronchospasm)
    ▪ Systemic corticosteroids (not short-acting, but used for moderate and severe exacerbations)
  ○ In recent years, additional medications have been made available for select subsets of patients with asthma, including the interleukin-5 (IL-5) antagonists benralizumab, mepolizumab, and reslizumab, and the interleukin-4 (IL-4) antagonist dupilumab, for the management of severe asthma with an eosinophilic phenotype (Prescribing information: Cinqair 2018, Dupixent 2018, Fasenra 2017, Nucala 2017). Additionally, tiotropium, long used for COPD, has been FDA-approved for the treatment of asthma (Spiriva Respimat prescribing information 2018).
  ○ ICSs are the most effective, most commonly recommended long-term control medications used for the treatment of asthma. The LABAs should not be used as monotherapy for the management of asthma due to increased risk for serious adverse events, including death. However, they are effective adjunctive therapy in patients who are not adequately controlled with an ICS alone. Theophylline and mast-cell stabilizers have weak to low efficacy in asthma. Theophylline has an unfavorable side-effect profile and may be life-threatening at high doses. Mast-cell stabilizers have a more favorable safety profile. Tiotropium is an option for add-on therapy in patients ≥ 12 years old with a history of exacerbations. An IL-5 antagonist or the immunoglobulin E (IgE) antagonist, omalizumab, may be added if patients require a higher level of care. Omalizumab is used in patients with moderate to severe allergic asthma while IL-5 antagonists are used for severe eosinophilic asthma. SABAs are the medication of choice for the relief of bronchospasm during acute exacerbations of asthma (Fasenra prescribing information 2017, NHLBI 2007, Global Initiative for Asthma [GINA] 2018).
• COPD is characterized by persistent respiratory symptoms and airflow limitation due to airway and/or alveolar abnormalities. The abnormalities are usually caused by exposure to noxious particles or gases. Airflow limitation is caused by a combination of small airway disease (eg, obstructive bronchiolitis) and parenchymal destruction (emphysema); the relative contributions of each component vary between patients. The most common symptoms of COPD include dyspnea, cough, and sputum production (Global Initiative for Chronic Obstructive Lung Disease [GOLD] 2019).
○ COPD affects 6.4% of the United States (U.S.) population and is the major contributor to mortality from chronic lower respiratory diseases, the third leading cause of death in the U.S. (Centers for Disease Control and Prevention 2017). Globally, COPD is the fourth leading cause of death and is expected to be the third leading cause of death by 2020; the burden of COPD continues to increase due to continued exposure to risk factors and aging of the population (GOLD 2019).
○ Cigarette smoking is the main risk factor for COPD; other risk factors include biomass fuel exposure (such as from cooking and heating in poorly ventilated dwellings) and air pollution. Host factors such as genetic abnormalities, abnormal lung development, and accelerated aging can predispose individuals to COPD development (GOLD 2019).
○ Patients with COPD may experience exacerbations, which are periods of acute worsening of respiratory symptoms (GOLD 2019).
○ Pharmacologic therapy for COPD can reduce symptoms, reduce the frequency and severity of exacerbations, and improve patients’ health status and exercise tolerance. There is no conclusive evidence that COPD medications modify the long-term decline in lung function characteristics of COPD (GOLD 2019).
○ Pharmacologic options for COPD treatment comprise several classes, including beta₂-agonists, anticholinergics, methylxanthines, ICSs, various combination products, and the phosphodiesterase (PDE)-4 inhibitor, roflumilast. Pharmacologic treatments should be individualized based on symptom severity, risk of exacerbations, side effects, comorbidities, drug availability, and cost, as well as the patient’s response, preference, and ability to use various drug delivery devices (GOLD 2019).
○ Inhaled bronchodilators are central to COPD symptom management, and are usually given on a regular basis to prevent or reduce symptoms. Several long-acting inhaled bronchodilators are available, and use of short-acting bronchodilators on a regular basis is not generally recommended (GOLD 2019).
○ Beta₂-agonists differ in their dosing requirements, pharmacokinetic parameters, and potential adverse effects. Several of the SABAs are available generically in at least 1 strength or formulation; however, there are no generic formulations for the LABAs.

This review includes the single-agent inhaled and oral beta₂-agonists. Although several agents are also available in combination inhalers along with an ICS or an anticholinergic, the combination products are not included in this review.
○ Tables in this review are organized by whether the drug product is short- or long-acting. Note that extended-release albuterol is categorized as short-acting for the purposes of this review, along with the other albuterol products.

Medispan class/subclass: Respiratory sympathomimetics/beta adrenergics

### Table 1. Medications Included Within Class Review

<table>
<thead>
<tr>
<th>Drug</th>
<th>Generic Availability</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Short-acting beta₂-agonists (oral and inhaled)</strong></td>
<td></td>
</tr>
<tr>
<td>albuterol inhalation aerosols and powder (ProAir HFA, ProAir RespIClick dry powder inhaler, Proventil HFA, Ventolin HFA)</td>
<td>-</td>
</tr>
<tr>
<td>albuterol solution for nebulization</td>
<td>✓</td>
</tr>
<tr>
<td>albuterol, oral tablets, extended-release tablets, and syrup</td>
<td>✓</td>
</tr>
<tr>
<td>levalbuterol inhalation aerosol (Xopenex HFA and generic)</td>
<td>- *</td>
</tr>
<tr>
<td>levalbuterol solution for nebulization (Xopenex and generics)</td>
<td>✓</td>
</tr>
<tr>
<td>metaproterenol, oral tablets and syrup</td>
<td>✓</td>
</tr>
<tr>
<td>terbutaline, oral tablets and injection</td>
<td>✓</td>
</tr>
<tr>
<td><strong>Long-acting beta₂-agonists (inhaled)</strong></td>
<td></td>
</tr>
<tr>
<td>Arcapta Neohaler (indacaterol) inhalation powder</td>
<td>-</td>
</tr>
<tr>
<td>Brovana (arformoterol) solution for nebulization</td>
<td>-</td>
</tr>
<tr>
<td>Perforomist (formoterol) solution for nebulization†</td>
<td>-</td>
</tr>
<tr>
<td>Serevent Diskus (salmeterol) inhalation powder</td>
<td>-</td>
</tr>
<tr>
<td>Striverdi Respimat (olodaterol) inhalation spray</td>
<td>-</td>
</tr>
</tbody>
</table>

Abbreviations: HFA = hydrofluoroalkane

* No A-rated generics have been approved by the FDA; however, an authorized generic is available.
† Formoterol was previously available as a dry powder inhaler (Foradil Aerolizer); however, this formulation is no longer marketed.

(‘Drugs@FDA 2018, Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations 2018’)

---

This information is considered confidential and proprietary to OptumRx. It is intended for internal use only and should be disseminated only to authorized recipients. The contents of the therapeutic class overviews on this website ("Content") are for informational purposes only. The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always seek the advice of a physician or other qualified health provider with any questions regarding a medical condition. Clinicians should refer to the full prescribing information and published resources when making medical decisions.
### INDICATIONS

**Table 2. Food and Drug Administration Approved Indications**

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Treatment and/or prevention of bronchospasm in patients with asthma/reversible obstructive airway disease</th>
<th>Prevention of exercise-induced bronchospasm</th>
<th>Maintenance treatment of bronchoconstriction/airflow obstruction in patients with COPD</th>
<th>Treatment of reversible bronchospasm occurring in association with emphysema and bronchitis</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Short-acting beta₂-agonists</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>albuterol</td>
<td>✓ *</td>
<td>✓ *†</td>
<td></td>
<td></td>
</tr>
<tr>
<td>levalbuterol</td>
<td>✓ †</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>metaproterenol</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>terbutaline</td>
<td>✓ §</td>
<td></td>
<td>✓ §</td>
<td></td>
</tr>
<tr>
<td><strong>Long-acting beta₂-agonists</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>aformoterol</td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>formoterol</td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>indacaterol</td>
<td></td>
<td>✓ **</td>
<td></td>
<td></td>
</tr>
<tr>
<td>olopatadine</td>
<td></td>
<td>✓ **</td>
<td></td>
<td></td>
</tr>
<tr>
<td>salmeterol</td>
<td>✓</td>
<td></td>
<td>¶</td>
<td>✓ ¶</td>
</tr>
</tbody>
</table>

**Abbreviations:** COPD = chronic obstructive pulmonary disease; HFA = hydrofluoroalkane

*Age ≥ 4 years (HFA inhalation aerosols and dry powder inhaler); age ≥ 2 (solution for nebulization); age ≥ 6 years (tablets and extended-release tablets)
†Inhalation aerosols and dry powder inhaler only
‡Age ≥ 4 years (Xopenex HFA); age ≥ 6 years (Xopenex inhalation solution)
§Age ≥ 12 years
||Only as a concomitant therapy with a long-term asthma control medication, such as an ICS
¶Age ≥ 4 years
**Indicated for long-term, once-daily maintenance treatment

- Information on indications, mechanism of action, pharmacokinetics, and safety has been obtained from the prescribing information for the individual products, except where noted otherwise.

### CLINICAL EFFICACY SUMMARY

- Clinical trials have demonstrated the efficacy of SABAs and LABAs in providing relief from asthma exacerbations, COPD exacerbations and exercise-induced asthma (EIA).

### SABAs: Asthma and COPD

- In the clinical trials that evaluated SABAs for the treatment of mild asthma, all SABAs have been shown to be efficacious in improving forced expiratory volume in 1 second (FEV₁). In the clinical trials that compared albuterol to levalbuterol, inconsistent results were found (Carl et al 2003, Gawchik et al 1999, Milgrom et al 2001, Nelson et al 1998, Nowak et al 2004, Nowak et al 2006, Qureshi et al 2005, Schreck et al 2005, Sepracor Trial 1, Sepracor Trial 2, Skoner et al 2001).
  - In 2 studies (1 retrospective, 1 prospective), levalbuterol resulted in a significantly lower hospitalization rate compared to albuterol (Carl et al 2003, Schreck et al 2005).
  - In another trial, when the 2 agents were given in the emergency department, there was no significant difference in the time to discharge (Skoner et al 2001).
  - Nowak et al also reported that there was no difference in the time to discharge from the emergency room with albuterol compared to levalbuterol (76 and 78.5 minutes; p = 0.74) (Nowak et al 2006).

- In an unpublished study, the difference in peak FEV1 was statistically significant for albuterol hydrofluoroalkanes (HFA) compared to levosalbuterol HFA (p = 0.018) (Sepracor Trial 2).
- Albuterol dry powder inhaler was compared to placebo dry powder inhaler in patients with asthma maintained on ICS treatment (Raphael et al 2014). Patients treated with albuterol dry powder inhaler had significantly improved FEV1 area under the curve compared to placebo. In patients with exercise-induced bronchoconstriction undergoing treadmill exercise challenge, placebo-treated patients had a greater decrease in FEV1 compared with albuterol dry powder inhaler-treated patients (Ostrom et al 2014). In a cumulative-dose, crossover study, albuterol dry powder inhaler was compared with albuterol HFA with similar between-group improvements in FEV1 at 30 minutes (Miller et al 2014). Additionally, albuterol dry powder inhaler demonstrated favorable FEV1 improvement in EIA compared to placebo in a crossover study (Ostrom et al 2015).

**LABAs: Asthma**

- The LABAs salmeterol and formoterol have been found to improve FEV1 in patients with mild to moderate asthma who require persistent use of SABAs. However, the SMART trial found that salmeterol had significant occurrences of combined respiratory-related deaths or respiratory-related life-threatening experiences compared to placebo (p < 0.05) (Nelson et al 2006). In a meta-analysis, salmeterol and formoterol both demonstrated an increase in severe exacerbations that required hospitalization, life-threatening exacerbations and asthma-related deaths in adults and children alike when compared to placebo (Salpérier et al 2006). Due to the results of these studies, all LABAs have a boxed warning stating that these agents may increase the risk of asthma-related death.

**LABAs: COPD**

- A systematic review concluded that in patients with COPD, there was no difference in the rate of mild exacerbations between patients treated with an ICS or LABA (odds ratio, 1.63; 95% confidence interval [CI], 0.49 to 5.39) or in the rate of moderate or severe COPD exacerbations (rate ratio, 0.96; 95% CI, 0.89 to 1.02) (Spencer et al 2011).
- Overall, data from published clinical trials demonstrated that treatment with indacaterol consistently results in significantly higher mean trough FEV1 after 12 weeks of treatment compared to placebo, formoterol, salmeterol and tiotropium. Patients treated with indacaterol also achieved significant improvements in COPD symptoms, as well as health-related quality of life compared to those treated with placebo. Compared to placebo, indacaterol significantly reduces the use of rescue medications, increases the days of no rescue medication use, and improves diary card-derived symptom variables (eg, nights with no awakenings, days with no daytime symptoms, days able to perform usual activities). In general, treatment with indacaterol is favored over other long-acting bronchodilators for these outcomes, but statistical superiority is not consistently achieved (Balint et al 2010, Buhl et al 2011, Chapman et al 2011, Dahl et al 2010, Donohue et al 2010, Feldman et al 2010, Gottfried et al 2012, Kerwin et al 2011, Korn et al 2011, Kornmann et al 2011, Magnussen et al 2010, Vogelmeier et al 2010). Recent meta-analyses comparing indacaterol to tiotropium and to twice-daily LABAs (salmeterol or formoterol) demonstrated that patients treated with indacaterol had higher trough FEV1 and greater improvements in the use of rescue medications and achieving improvements in dyspnea and health status compared to the alternative treatments. However, the trials included in this meta-analysis used indacaterol doses higher than FDA-approved daily doses of 75 mcg (Cope et al 2013, Rodrigo et al 2012).
- Placebo-controlled trials demonstrate that within 5 minutes after administration of indacaterol, significant improvements in bronchodilation are achieved (Balint et al 2010, Donohue et al 2010, Gottfried et al 2012, Kerwin et al 2011,
Magnussen et al 2010, Vogelmeier et al 2010). These results have also been observed when comparing indacaterol to salmeterol, salmeterol/fluticasone, and tiotropium (Buhl et al 2011, Korn et al 2011, Vogelmeier et al 2010).

• In 2 studies, patients diagnosed with COPD were treated with arformoterol, salmeterol, or placebo. These studies found that both arformoterol and salmeterol significantly improved morning trough FEV\textsubscript{1} throughout the 12 weeks of daily treatment compared to placebo (p < 0.001 in both trials) (Baumgartner et al 2007, Sepracor, 2005). In a head-to-head study against salmeterol, formoterol was associated with a greater change from baseline in FEV\textsubscript{1} at 5 minutes post-dose on day 28 (p = 0.022) (Cote et al 2009). Currently, there is a lack of head-to-head randomized, double-blind clinical trials to determine a preferential status of one agent over another for the treatment of COPD.

• Two replicate, multicenter, randomized, double-blind, placebo-controlled, parallel-group, Phase 3 studies investigated the long-term efficacy and safety of once-daily olodaterol via Respimat soft-mist inhaler vs placebo and formoterol over 48 weeks in patients with moderate to very severe COPD receiving usual-care background therapy. Patients were randomized to receive once-daily olodaterol 5 or 10 mcg, twice-daily formoterol 12 mcg, or placebo. Co-primary endpoints were FEV\textsubscript{1} area under the curve from 0 to 3 hours (AUC\textsubscript{0-3}), trough FEV\textsubscript{1}, and Mahler transition dyspnea index (TDI) total score after 24 weeks. Overall, in Study 1222.13 (N = 904) and Study 1222.14 (N = 934), patients who received treatment with olodaterol had significantly improved FEV\textsubscript{1} AUC\textsubscript{0-3} vs placebo in both studies (p < 0.0001 for all comparisons) and trough FEV\textsubscript{1} vs placebo (p < 0.01). Formoterol also showed statistically significant differences in both Study 1222.13 (p < 0.01) and Study 1222.14 (p < 0.05) (Koch et al 2014).

• Two replicate, randomized, double-blind, placebo-controlled, parallel-group, Phase 3 trials investigated the long-term safety and efficacy of olodaterol in patients with moderate to very severe COPD receiving usual-care background therapy. Patients received olodaterol 5 mcg or 10 mcg or placebo once daily for 48 weeks. Co-primary endpoints were FEV\textsubscript{1} AUC\textsubscript{0-3} (change from baseline) and trough FEV\textsubscript{1} at 12 weeks. Overall, Study 1222.11 (N = 624) and Study 1222.12 (N = 642) showed that olodaterol 5 mcg and 10 mcg significantly improved the FEV\textsubscript{1} AUC\textsubscript{0-3} response (p < 0.0001) and trough FEV\textsubscript{1} (Study 1222.11, p < 0.0001; Study 1222.12, p < 0.05, post hoc) at week 12. The incidence of adverse events was comparable with that of placebo (Ferguson et al 2014).

• Two replicate, multicenter, randomized, double-blind, double-dummy, placebo-controlled, 4-way cross-over group, Phase 3 studies investigated the long-term efficacy and safety of once-daily olodaterol via Respimat soft-mist inhaler vs placebo and formoterol over 6 weeks in patients with moderate to very severe COPD receiving usual-care background therapy. Patients were randomized to receive once-daily olodaterol 5 or 10 mcg, twice-daily formoterol 12 mcg, or placebo. Co-primary endpoints were FEV\textsubscript{1} area under the curve from 0 to 12 hours (AUC\textsubscript{0-12}) and FEV\textsubscript{1} area under the curve from 12 to 24 hours (AUC\textsubscript{12-24}) after 6 weeks. Overall, in Study 1222.24 (N = 99) and Study 1222.25 (N = 100), patients who received treatment with both doses of olodaterol and formoterol had significantly improved FEV\textsubscript{1} profiles (co-primary endpoints of FEV\textsubscript{1} AUC\textsubscript{0-12} and FEV\textsubscript{1} AUC\textsubscript{12-24} and the key secondary endpoint [FEV\textsubscript{1} AUC\textsubscript{0-24}] vs placebo in both studies for all comparisons p < 0.0001). No statistically significant differences were reported between the 3 active comparators (Feldman et al 2014).

• A meta-analysis that compared LABAs (salmeterol, formoterol, and indacaterol) to tiotropium demonstrated that tiotropium was more effective than LABAs as a group in preventing COPD exacerbations and disease-related hospitalizations. However, overall hospitalization rates, mortality, symptom improvement, and changes in lung function were similar among groups (Chong et al 2012). Another meta-analysis compared the use of LABAs plus tiotropium to the use of either LABAs alone or tiotropium alone. The analysis demonstrated that there was a significant improvement in FEV\textsubscript{1} with combination therapy compared to tiotropium alone. However, overall change from baseline in health-related quality of life for patients receiving a LABA plus tiotropium compared to tiotropium alone, and the clinical significance of this small difference is unclear. Hospital admissions and mortality were not significantly different between groups. Data comparing LABA plus tiotropium to LABA alone were somewhat limited, but demonstrated a significant improvement in health-related quality of life, FEV\textsubscript{1} and exacerbations (Farne et al 2015).

EIA

• For the treatment of EIA, albuterol, metaproterenol, and formoterol have demonstrated an improvement in FEV\textsubscript{1} compared to placebo (Berkowitz et al 1986, Bonini et al 2013, Edelman et al 2000, Richter et al 2002, Shapiro et al 2002, Storms et al 2004).
  ○ In 1 study, albuterol- and metaproterenol-treated patients had a lower incidence of exercise-induced bronchospasm compared to placebo (Cote et al 2009).
○ In another study comparing albuterol, formoterol and placebo for EIA, both active treatment groups provided a statistically significant decrease in mean maximum percent of FEV₁ compared to placebo (p < 0.01) (Shapiro et al 2002).

### CLINICAL GUIDELINES

#### Asthma

- The National Asthma Education and Prevention Program (NAEPP) guideline from the NHLBI states that the initial treatment of asthma should correspond to the appropriate asthma severity category, and it provides a stepwise approach to asthma management. Long-term control medications such as ICSs, long-acting bronchodilators, leukotriene modifiers, cromolyn, theophylline, and immunomodulators should be taken daily on a long-term basis to achieve and maintain control of persistent asthma. ICSs are the most potent and consistently effective long-term asthma control medication. Quick-relief medications such as SABAs and anticholinergics are used to provide prompt relief of bronchoconstriction and accompanying acute symptoms such as cough, chest tightness, and wheezing. Systemic corticosteroids are important in the treatment of moderate or severe exacerbations because these medications prevent progression of the exacerbation, speed recovery, and prevent relapses (NHLBI 2007).  
  - LABAs are used in combination with ICSs for long-term control and prevention of symptoms in moderate or severe persistent asthma.  
  - Of the adjunctive treatments available, a LABA is the preferred option to combine with an ICS in patients 12 years of age and older. This combination is also an option in selected patients 5 to 12 years of age.  
- The Global Initiative for Asthma (GINA) guideline also provides a stepwise approach to asthma management. It recommends an ICS as a preferred controller medication choice, with an increased ICS dose and/or addition of a LABA for increasing symptom severity (higher steps). At the highest step, it is recommended that the patient be referred for add-on treatment (eg, tiotropium, omalizumab, mepolizumab) (GINA 2018).

#### COPD

- The 2018 GOLD guidelines state that the management strategy for stable COPD should be predominantly based on an assessment of the patient’s symptoms and future risk of exacerbations. The risk of exacerbations is now based solely on the exacerbation history, whereas in previous versions of the guideline, risk assessment also included consideration of airflow limitation assessed by spirometry. Key recommendations from the GOLD guidelines are as follows (GOLD 2019):  
  - Inhaled bronchodilators are recommended over oral bronchodilators.  
  - LAMAs and LABAs are preferred over short-acting agents except for patients with only occasional dyspnea.  
  - Patients may be started on single long-acting bronchodilator therapy or dual long-acting bronchodilator therapy. In patients with persistent dyspnea on 1 bronchodilator, treatment should be escalated to 2.  
  - Long-term monotherapy with ICSs is not recommended. Long-term treatment with ICSs may be considered in association with LABAs for patients with a history of exacerbations despite treatment with long-acting bronchodilators.  
  - Treatment recommendations are given for patients with COPD based on their GOLD patient group (see Table 3 below).  
    - **Group A:** Patients should be offered bronchodilator treatment (short- or long-acting), based on its effect on breathlessness. This should be continued if symptomatic benefit is documented.  
    - **Group B:** Initial therapy should consist of a long-acting bronchodilator (LAMA or LABA). For patients with persistent breathlessness on monotherapy, use of 2 bronchodilators is recommended (LAMA + LABA). For patients with severe breathlessness, initial therapy with 2 bronchodilators may be considered. If the addition of a second bronchodilator does not improve symptoms, it is suggested that treatment could be stepped down to a single bronchodilator; switching to another device or molecules can also be considered.  
    - **Group C:** Initial therapy should be a LAMA. Patients with persistent exacerbations may benefit from adding a second long-acting bronchodilator (LAMA + LABA, preferred) or using an ICS + LABA. For patients who have a history and/or findings suggestive of asthma-COPD overlap or blood eosinophil count ≥ 300 cells/µL, ICS + LABA is preferred.  
    - **Group D:** In general, it is recommended to start therapy with a LAMA. For patients with more severe symptoms, especially dyspnea and/or exercise limitation, LAMA/LABA may be considered for initial treatment. In some patients, initial therapy with an ICS + LABA may be the first choice; these patients may have a history and/or findings suggestive of asthma-COPD overlap or blood eosinophil count ≥ 300 cells/µL. In patients who develop further exacerbations on LAMA + LABA therapy, alternative pathways include escalation to a LAMA + LABA + ICS.
(preferred) or a switch to an ICS + LABA. If patients treated with a LAMA + LABA + ICS still have exacerbations, options for selected patients may include addition of roflumilast, addition of a macrolide, or stopping the ICS.

Table 3. Assessment of symptoms and risk of exacerbations to determine GOLD patient group

<table>
<thead>
<tr>
<th>Exacerbation history</th>
<th>Symptoms</th>
<th>mMRC 0 to 1</th>
<th>mMRC ≥ 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 2 (or ≥ 1 leading to hospital admission)</td>
<td>C</td>
<td>CAT &lt; 10</td>
<td>D</td>
</tr>
<tr>
<td>0 or 1 (not leading to hospital admission)</td>
<td>A</td>
<td>CAT ≥ 10</td>
<td>B</td>
</tr>
</tbody>
</table>

Abbreviations: CAT = COPD assessment test; mMRC = modified British Medical Research Council questionnaire

• Guidelines for the prevention of acute exacerbations of COPD from the American College of Chest Physicians and the Canadian Thoracic Society state that a LAMA is recommended over either a short-acting muscarinic antagonist or a LABA. The guidelines state that certain combination bronchodilators or bronchodilator/ICS combinations may reduce exacerbations, but does not state that any combination is superior to LAMA monotherapy in patients with stable COPD (Criner et al 2015).

Exercise-induced bronchoconstriction
• For exercise-induced bronchoconstriction, guidelines from the American Thoracic Society recommend administration of an inhaled SABA 15 minutes prior to exercise. The guidelines also recommend a controller agent added whenever SABA therapy is used at least once daily. Additional guidelines are set forth for patients with symptoms despite using an inhaled SABA before exercise (Parsons et al 2013). Joint guidelines from the American Academy of Allergy, Asthma & Immunology, the American College of Allergy, Asthma & Immunology, and the American College of Allergy, Asthma & Immunology state that beta2-agonists (SABAs or LABAs) are most effective at short-term protection against exercise-induced bronchoconstriction and for accelerating recovery from exercise-induced bronchoconstriction. However, daily use of a SABA or LABA will lead to tolerance. Additional or adjunctive options include daily use of leukotriene inhibitors or ICSs, cromolyn sodium before exercise, or ipratropium for patients who have not responded to other agents (Weiler et al 2016).

SAFETY SUMMARY
• Contraindications:
  ○ Serevent Diskus and ProAir RespiClick are contraindicated in patients with a severe hypersensitivity to milk proteins.
  ○ LABAs should generally not be used as a primary treatment of status asthmaticus or other acute episodes of asthma or COPD that require intensive measures; this is listed as a contraindication for Serevent Diskus.
  ○ All LABAs are contraindicated for use in patients with asthma without concomitant use of a long-term asthma control medication.
• Key warnings and precautions:
  ○ All LABAs have a boxed warning describing the increased risk of asthma-related deaths. Because of this risk, use of LABAs for the treatment of asthma without a concomitant long-term asthma control medication, such as an ICS, is contraindicated. LABAs should be used only as additional therapy for patients with asthma who are currently taking but are inadequately controlled on a long-term asthma control medication, such as an ICS.
  ○ Beta2-agonists may also lead to:
    ▪ paradoxical bronchospasm
    ▪ fatalities with excessive use
    ▪ cardiovascular effects such as increased heart rate, blood pressure, and/or electrocardiogram changes
    ▪ central nervous system effects and/or seizures
  ○ LABAs should not be used to treat acute symptoms or initiated in the setting of acutely deteriorating asthma or COPD.
• Adverse events
  ○ Commonly-reported adverse events (≥ 5% for at least 1 medication in the class) include chest pain, palpitations, tachycardia, dizziness, excitement, fatigue, headache, nervousness, shakiness, somnolence, tremor, rash, diarrhea,
nausea, vomiting, pain, asthma exacerbation, bronchitis, cough, influenza, nasal congestion, nasopharyngitis/pharyngitis, respiratory disorder, rhinitis, throat irritation, upper respiratory tract infection, viral respiratory infection, accidental injury, fever, and viral infection.

- Albuterol, levalbuterol, metaproterenol, terbutaline, arformoterol, indacaterol, and salmeterol are Pregnancy Category C; ProAir RespiClick, formoterol, and olodaterol are not currently assigned a Pregnancy Category.

## DOSSING AND ADMINISTRATION

### Table 4. Dosing and Administration

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Available Formulations</th>
<th>Route</th>
<th>Usual Recommended Frequency</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Short-acting beta&lt;sub&gt;2&lt;/sub&gt;-agonists</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>albuterol</td>
<td>Inhalation: metered dose aerosol inhaler (HFA), metered dose dry powder inhaler, solution for nebulization Oral: extended-release tablets, syrup, tablets</td>
<td>Inhalation, oral</td>
<td>Treatment or prevention of bronchospasm in patients with asthma: · Aerosol/dry powder inhaler: 1 to 2 inhalations every 4 to 6 hours · Solution for nebulization: 3 to 4 times daily · Extended-release tablets: twice daily · Syrup, tablets: 3 to 4 times daily</td>
<td>Exercise-induced bronchospasm: · Aerosol/dry powder inhaler: 2 inhalations 15 to 30 minutes before exercise</td>
</tr>
<tr>
<td>levalbuterol</td>
<td>Metered dose aerosol inhaler (HFA), solution for nebulization</td>
<td>Inhalation</td>
<td>Treatment or prevention of bronchospasm in patients with asthma: · Aerosol inhaler: 1 to 2 inhalations every 4 to 6 hours · Solution for nebulization: 3 times daily</td>
<td></td>
</tr>
<tr>
<td>metaproterenol</td>
<td>Syrup, tablets</td>
<td>Oral</td>
<td>3 to 4 times daily</td>
<td></td>
</tr>
<tr>
<td>terbutaline</td>
<td>Injection, tablets</td>
<td>Subcutaneous injection, oral</td>
<td>· Injection: 1 subcutaneous injection, may repeat in 15 to 30 minutes if improvement does not occur; maximum, 0.5 mg in 4 hours · Tablets: 3 times daily, 6 hours apart</td>
<td>Injection: Safety and efficacy in children &lt; 12 years of age have not been established.</td>
</tr>
<tr>
<td><strong>Long-acting beta&lt;sub&gt;2&lt;/sub&gt;-agonists</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>arformoterol</td>
<td>Solution for nebulization</td>
<td>Inhalation</td>
<td>Twice daily</td>
<td>Safety and efficacy in children have not been established.</td>
</tr>
<tr>
<td>formoterol</td>
<td>Solution for nebulization</td>
<td>Inhalation</td>
<td>Twice daily</td>
<td>Safety and efficacy in children have not been established.</td>
</tr>
<tr>
<td>indacaterol</td>
<td>Capsule for inhalation</td>
<td>Inhalation</td>
<td>Once daily</td>
<td>Safety and efficacy in children have not been established.</td>
</tr>
<tr>
<td>Generic Name</td>
<td>Available Formulations</td>
<td>Route</td>
<td>Usual Recommended Frequency</td>
<td>Comments</td>
</tr>
<tr>
<td>--------------</td>
<td>------------------------</td>
<td>-------</td>
<td>-----------------------------</td>
<td>----------</td>
</tr>
<tr>
<td>olodaterol</td>
<td>Inhalation spray</td>
<td>Inhalation</td>
<td>Once daily</td>
<td>Safety and efficacy in children have not been established.</td>
</tr>
<tr>
<td>salmeterol</td>
<td>Dry powder inhaler</td>
<td>Inhalation</td>
<td>Treatment or prevention of bronchospasm in patients with asthma/maintenance treatment of bronchoconstriction in COPD 1 inhalation twice daily</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Exercise-induced bronchospasm: 1 inhalation at least 30 minutes before exercise</td>
</tr>
</tbody>
</table>

Abbreviations: COPD = chronic obstructive pulmonary disease; HFA = hydrofluoroalkane

See the current prescribing information for full details.

**CONCLUSION**

- Single-entity respiratory beta2-agonist agents are FDA-approved for the treatment of asthma, COPD, reversible airway obstruction and/or exercise-induced bronchospasm.
  - Beta2-agonists are classified as short- or long-acting based on their onset and duration of action, and are available in various dosage forms, including solution for nebulization, aerosol inhaler, dry powder inhaler, oral solution, immediate- and extended-release tablets, and solution for injection.
  - SABAs are generally dosed multiple times per day for the treatment or prevention of symptoms.
  - LABAs are typically administered twice daily for COPD, with the exception of indacaterol and olodaterol, which are administered once daily.

- Overall, SABAs have demonstrated similar efficacy and safety. Similarly, guidelines do not recommend one LABA over another, and head-to-head clinical trials have not determined the superiority of any one agent.

- All LABAs have a boxed warning stating that these agents may increase the risk of asthma-related death.
  - In the treatment of asthma, LABAs should not be used as monotherapy, but rather added on to another long-acting controller medication such as an ICS if patients are not adequately controlled on the ICS alone.

- GINA and NHLBI guidelines recommend SABAs for symptomatic relief in patients with asthma, which should generally be used on an as-needed or "rescue" basis. For chronic management of asthma, LABAs should be used as add-on therapy in patients not adequately controlled on an ICS as an alternative to maximizing the ICS dose.
  - LABAs may also be used for exercise-induced bronchospasm and provide a longer period of coverage (typically 12 hours or more) compared to the SABAs; however, daily use of a beta2-agonist can lead to tolerance, and daily use of LABA monotherapy is not recommended.

- GOLD guidelines state that inhaled bronchodilators are a key component of COPD treatment, and long-acting agents are generally preferred over short-acting agents for maintenance therapy.
  - Depending on the COPD patient subtype, initial COPD management may include use of a beta2-agonist and/or an anticholinergic agent.

- None of the current asthma or COPD treatment guidelines recommend the use of one specific inhaled beta2-agonist product over another.
  - Administration instructions and inhalation devices vary among products and should be considered in product selection.

**REFERENCES**

- Cinquair [package insert], Frazer, PA: Teva; September 2018.